New asthma drug candidate PA9159 passes first safety check in healthy volunteers

NCT ID NCT06916273

Completed Disease control Sponsor: Anhui Palo Alto Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new asthma medication called PA9159, given as an inhaled aerosol, in 40 healthy adults in China. The main goal was to see if it is safe and how the body processes it. Researchers monitored side effects, vital signs, and lab tests after single and repeated doses. This is a first step before testing the drug in people with asthma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PA9159 (a novel corticosteroid) inhalation aerosol
What this could lead to: If successful, this could lead to a new inhaled corticosteroid for controlling asthma symptoms.
What could go wrong: This is an early Phase 1 safety trial in healthy people, not asthma patients. It only checks safety and dosing, not whether the drug works for asthma. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIAL ASTHMA

Contacts and locations

Locations

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.